查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1833549

2032 年奈米粒子药物传输市场预测：按类型、材料、给药途径、应用、最终用户和地区进行的全球分析

Nanoparticles for Drug Delivery Market Forecasts to 2032 - Global Analysis By Type, Material, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球药物输送奈米粒子市场预计在 2025 年达到 1.057 亿美元，到 2032 年将达到 1.801 亿美元，预测期内的复合年增长率为 7.9%。

药物递送奈米颗粒是一种超小型载体，旨在将治疗药物直接输送至目标细胞和组织。这些颗粒可增强药物的溶解度、稳定性和生物有效性，同时最大限度地减少副作用。奈米颗粒可由脂质、聚合物、金属和蛋白质製成，用于治疗癌症、感染疾病和慢性疾病。奈米颗粒可实现控释、穿透生物屏障和精准标靶化。其尺寸和表面特性可进行定制，以优化与生物系统的相互作用，从而实现有效治疗。

根据美国国立卫生研究院介绍，奈米粒子可以跨越生物屏障，实现标靶药物输送，提高生物有效性，并最大限度地减少治疗癌症和慢性疾病的副作用。

患有慢性病和癌症的人数不断增加

心血管疾病、糖尿病，尤其是癌症等慢性疾病的日益流行，推动了对奈米颗粒药物递送系统的需求。这些平台具有更高的生物有效性、更强的标靶性并减少副作用，使其成为长期疾病管理的理想选择。随着全球癌症患者数量的快速增长，奈米颗粒越来越多地应用于化疗和标靶治疗。这种医疗需求正在推动创新和应用，使奈米颗粒成为推进肿瘤、代谢和神经系统疾病现代治疗方法的关键推动因素。

奈米产品的监管复杂性

严格的法律规范是奈米颗粒药物递送市场发展的一大限制因素。由于FDA和EMA等机构要求进行复杂的安全性、毒性和有效性评估，奈米药物通常需要较长的核准时间。缺乏全球统一的指导方针进一步加剧了全球商业化的复杂性。这些挑战增加了研发成本，延迟了产品上市，并阻碍了中小企业进入市场。因此，儘管各治疗领域对创新奈米颗粒递送平台的临床需求强劲，但监管的复杂性阻碍了其快速推广。

奈米颗粒疫苗和基因治疗

奈米颗粒疫苗和基因疗法的进展为该市场带来了巨大的机会。奈米载体能够增强遗传物质的稳定性、标靶递送和细胞摄取，从而显着改善治疗效果。它们在针对COVID-19的mRNA疫苗中的应用证明了脂质奈米颗粒的潜力，为其在感染疾病和罕见遗传疾病中的广泛应用铺平了道路。个人化医疗和先进生技药品领域不断增长的投资进一步拓展了这些机会，使奈米颗粒成为具有临床和商业性前景的下一代疗法的关键工具。

与替代技术的竞争

来自替代药物递送技术的竞争对市场扩张构成了威胁。单株抗体、病毒载体和先进聚合物疗法等平台也提供标靶递送，且疗效已得到验证。这些成熟的治疗方法具有更清晰的监管途径和临床医生熟悉度的优点。如果奈米颗粒未能展现出卓越的安全性、成本效益和扩充性，则有可能失去市场份额。因此，竞争平台的存在对市场成长构成了挑战，迫使奈米颗粒创新者不断透过创新和治疗性能实现差异化。

COVID-19的影响：

COVID-19疫情显着加速了奈米颗粒药物递送技术的普及，尤其是mRNA疫苗中的脂质奈米颗粒。这项全球性的成功案例凸显了奈米载体在快速疫苗研发中的扩充性和有效性。研发资金的增加和政府支持的增加推动了奈米载体在免疫学、肿瘤学和感染疾病的更广泛应用。儘管初期供应链中断阻碍了临床试验，但自疫情爆发以来，对奈米医学的投资激增。整体而言，COVID-19疫情已将奈米颗粒定位为现代医疗保健的重要工具，激发了信任、创新以及药物递送平台未来产品线的拓展。

脂质体市场预计将成为预测期内最大的市场

脂质体领域预计将在预测期内占据市场主导地位，因为它具有成熟的安全性、生物相容性以及包封亲水性和疏水性药物的能力。脂质体广泛应用于癌症治疗、抗真菌治疗、疫苗等领域，因为它们能够改善标靶递送、降低全身毒性并提高药物溶解度。广泛的临床应用和FDA核准巩固了脂质体製剂的市场地位。像Doxil）这样的脂质体製剂的成功凸显了其治疗相关性，并确保了其在奈米颗粒药物递送领域的持续主导地位。

预计预测期内聚合物基细分市场将以最高复合年增长率成长

受可生物降解聚合物的进步及其在药物传输领域的多功能性推动，聚合物基奈米颗粒市场预计将以最高的复合年增长率成长。这些载体可实现控释、延长循环时间和精准靶向，使其在癌症、基因治疗和神经系统疾病领域中发挥重要作用。聚合物化学领域的快速创新正在支持更安全、更有效的製剂。在不断增加的研发投入以及製药公司和研究机构之间合作的推动下，聚合物基奈米颗粒正迅速发展成为奈米医学领域的前沿领域。

占比最大的地区：

由于医疗保健投资的增加、癌症盛行率的上升以及製药製造地的扩张，预计亚太地区将在预测期内占据最大的市场份额。中国、印度和日本等国家正大力投资奈米技术研究和临床应用。积极的政府措施、经济高效的生产能力以及对先进疗法日益增长的需求，进一步推动了奈米技术的应用。此外，学术机构和製药公司之间的合作正在加速临床试验，使亚太地区成为奈米颗粒药物传输应用的领先地区。

复合年增长率最高的地区：

由于强大的研发能力、先进的医疗基础设施以及创新治疗方法的早期应用，北美预计将在预测期内实现最高的复合年增长率。美国凭藉大量经FDA核准的基于奈米颗粒的药物和疫苗，在生技公司和政府机构的大量投资支持下，处于领先地位。优惠的报销框架、日益增长的慢性病盛行率以及强大的临床试验管道进一步推动了这一增长。北美在奈米医学创新领域的领导地位巩固了其作为成长最快的区域市场的地位。

免费客製化服务：

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球药物传输奈米颗粒市场（按类型）

  • 脂质体
  • 囊泡
  • 胶束
  • 固体脂质奈米粒
  • 奈米乳液
  • 聚合物奈米粒子

6. 全球药物传输奈米颗粒市场（依材料）

  • 脂质基
  • 聚合物基
  • 金属
  • 量子点
  • 树状聚合物
  • 碳基

7. 全球药物传输奈米颗粒市场（依给药途径）

  • 口服
  • 静脉
  • 外用
  • 肺
  • 鼻腔
  • 眼科
  • 经皮

8. 全球药物传输奈米颗粒市场（依应用）

  • 癌症治疗
  • 心血管疾病
  • 神经系统疾病
  • 感染疾病
  • 疫苗

9. 全球药物传输奈米颗粒市场（依最终用户）

  • 医院
  • 製药公司
  • 研究办公室
  • 生技公司

10. 全球药物传输奈米颗粒市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 12 章：公司概况

  • Merck & Co.
  • Pfizer
  • Johnson & Johnson
  • Novartis
  • Roche
  • AbbVie
  • Sanofi
  • Amgen
  • Celgene
  • Gilead Sciences
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Biogen
  • Eli Lilly
  • Regeneron Pharmaceuticals
  • Medtronic
  • MedImmune
Product Code: SMRC31382

According to Stratistics MRC, the Global Nanoparticles for Drug Delivery Market is accounted for $105.7 million in 2025 and is expected to reach $180.1 million by 2032 growing at a CAGR of 7.9% during the forecast period. Nanoparticles for drug delivery are ultra-small carriers designed to transport therapeutic agents directly to targeted cells or tissues. These particles enhance drug solubility, stability, and bioavailability while minimizing side effects. They can be engineered from lipids, polymers, metals, or proteins and are used in treating cancer, infections, and chronic diseases. Nanoparticles enable controlled release, crossing biological barriers, and precision targeting. Their size and surface properties are tailored to optimize interaction with biological systems for effective treatment.

According to NIH, nanoparticles enable targeted drug delivery by crossing biological barriers, improving bioavailability, and minimizing side effects in cancer and chronic disease therapies.

Market Dynamics:

Driver:

Rising chronic and cancer cases

The growing prevalence of chronic diseases, including cardiovascular disorders, diabetes, and especially cancer, is fueling demand for nanoparticle-based drug delivery systems. These platforms improve bioavailability, target precision, and reduce side effects, making them ideal for managing long-term illnesses. With cancer cases surging globally, nanoparticles are increasingly deployed in chemotherapy and targeted treatments. This medical necessity drives innovation and adoption, positioning nanoparticles as a critical enabler in advancing modern therapeutics across oncology, metabolic diseases, and neurological conditions.

Restraint:

Regulatory complexities for nano products

Stringent regulatory frameworks act as a major restraint for the nanoparticle drug delivery market. Nanomedicines often face lengthy approval timelines due to complex safety, toxicity, and efficacy evaluations required by agencies like the FDA and EMA. The absence of universally harmonized guidelines further complicates global commercialization. These challenges increase R&D costs and delay product launches, deterring smaller companies from market entry. Consequently, regulatory complexities hinder rapid adoption, despite strong clinical demand for innovative nanoparticle-based delivery platforms across therapeutic segments.

Opportunity:

Nanoparticle vaccines and gene therapy

Advancements in nanoparticle-enabled vaccines and gene therapy present immense opportunities for this market. Nanocarriers enhance stability, targeted delivery, and cellular uptake of genetic material, significantly improving treatment outcomes. Their use in mRNA COVID-19 vaccines showcased the potential of lipid nanoparticles, setting a precedent for broader applications in infectious diseases and rare genetic disorders. Growing investment in personalized medicine and advanced biologics further expands these opportunities, positioning nanoparticles as pivotal tools in next-generation therapies with high clinical and commercial promise.

Threat:

Competition from alternative technologies

Competition from alternative drug delivery technologies poses a threat to market expansion. Platforms like monoclonal antibodies, viral vectors, and advanced polymer therapeutics are also achieving targeted delivery with proven efficacy. These established modalities often benefit from clearer regulatory pathways and clinician familiarity. If nanoparticles fail to demonstrate superior safety, cost-effectiveness, and scalability, they risk losing adoption share. Consequently, the presence of competing platforms challenges market growth, compelling nanoparticle innovators to continuously differentiate through innovation and therapeutic performance.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated nanoparticle drug delivery adoption, especially through lipid nanoparticles in mRNA vaccines. This global success story highlighted the scalability and efficacy of nanocarriers in rapid vaccine development. Increased R&D funding and government support propelled broader applications in immunology, oncology, and infectious diseases. While early supply chain disruptions hampered clinical trials, post-pandemic investments in nanomedicine surged. Overall, COVID-19 positioned nanoparticles as indispensable tools in modern healthcare, catalyzing trust, innovation, and future pipeline expansion for drug delivery platforms.

The liposomes segment is expected to be the largest during the forecast period

The liposomes segment is projected to dominate the market during the forecast period, owing to their established safety profile, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic drugs. Liposomes improve targeted delivery, reduce systemic toxicity, and enhance drug solubility, making them widely used in cancer therapy, antifungal treatments, and vaccines. Strong clinical adoption and FDA approvals reinforce their market position. The success of liposomal formulations like Doxil highlights their therapeutic relevance, ensuring continued dominance within nanoparticle-based drug delivery.

The polymer-based segment is expected to have the highest CAGR during the forecast period

The polymer-based nanoparticles segment is forecasted to witness the highest CAGR, impelled by advancements in biodegradable polymers and their versatility in drug delivery. These carriers enable controlled release, prolonged circulation time, and precise targeting, making them valuable in cancer, gene therapy, and neurological disorders. Rapid innovation in polymer chemistry supports safer and more effective formulations. Increasing R&D investments and collaborations between pharmaceutical firms and research institutions are fueling growth, positioning polymer-based nanoparticles as a rapidly expanding frontier in nanomedicine.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising healthcare investments, growing cancer prevalence, and expansion of pharmaceutical manufacturing hubs. Countries such as China, India, and Japan are investing heavily in nanotechnology research and clinical applications. Favorable government initiatives, cost-effective production capabilities, and rising demand for advanced therapies further boost adoption. Additionally, collaborations between academic institutions and pharmaceutical companies accelerate clinical trials, making Asia Pacific a leading region in nanoparticle drug delivery adoption.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to strong R&D capabilities, advanced healthcare infrastructure, and early adoption of innovative therapies. The U.S. is at the forefront with numerous FDA-approved nanoparticle-based drugs and vaccines, supported by significant investments from biotech firms and government agencies. Favorable reimbursement frameworks, rising incidence of chronic diseases, and robust clinical trial pipelines further accelerate growth. North America's leadership in nanomedicine innovation ensures its position as the fastest-growing regional market.

Key players in the market

Some of the key players in Nanoparticles for Drug Delivery Market include Merck & Co., Pfizer, Johnson & Johnson, Novartis, Roche, AbbVie, Sanofi, Amgen, Celgene, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Biogen, Eli Lilly, Regeneron Pharmaceuticals, Medtronic, and MedImmune.

Key Developments:

In August 2025, Merck & Co. launched a lipid nanoparticle platform for oncology mRNA delivery, optimizing tumor targeting while minimizing systemic toxicity. This innovation advances precision cancer therapeutics, improving safety and treatment outcomes.

In July 2025, Pfizer introduced a polymeric nanoparticle intranasal vaccine formulation, designed to strengthen mucosal immunity. By simplifying administration and logistics, it supports large-scale immunization programs with improved efficacy and patient accessibility.

In June 2025, Johnson & Johnson unveiled a dual-layer nanoparticle system for autoimmune therapies, enabling sequential release of immunomodulators. This controlled delivery approach enhances therapeutic efficacy, reduces side effects, and supports long-term immune regulation.

Types Covered:

  • Liposomes
  • Niosomes
  • Micelles
  • Solid Lipid Nanoparticles
  • Nanoemulsions
  • Polymeric Nanoparticles

Materials Covered:

  • Lipid-Based
  • Polymer-Based
  • Metallic
  • Quantum Dots
  • Dendrimers
  • Carbon-Based

Route of Administrations Covered:

  • Oral
  • Intravenous
  • Topical
  • Pulmonary
  • Nasal
  • Ocular
  • Transdermal

Applications Covered:

  • Cancer Therapy
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Vaccines

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Research Laboratories
  • Biotechnology Firms

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanoparticles for Drug Delivery Market, By Type

  • 5.1 Introduction
  • 5.2 Liposomes
  • 5.3 Niosomes
  • 5.4 Micelles
  • 5.5 Solid Lipid Nanoparticles
  • 5.6 Nanoemulsions
  • 5.7 Polymeric Nanoparticles

6 Global Nanoparticles for Drug Delivery Market, By Material

  • 6.1 Introduction
  • 6.2 Lipid-Based
  • 6.3 Polymer-Based
  • 6.4 Metallic
  • 6.5 Quantum Dots
  • 6.6 Dendrimers
  • 6.7 Carbon-Based

7 Global Nanoparticles for Drug Delivery Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Topical
  • 7.5 Pulmonary
  • 7.6 Nasal
  • 7.7 Ocular
  • 7.8 Transdermal

8 Global Nanoparticles for Drug Delivery Market, By Application

  • 8.1 Introduction
  • 8.2 Cancer Therapy
  • 8.3 Cardiovascular Diseases
  • 8.4 Neurological Disorders
  • 8.5 Infectious Diseases
  • 8.6 Vaccines

9 Global Nanoparticles for Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Research Laboratories
  • 9.5 Biotechnology Firms

10 Global Nanoparticles for Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Merck & Co.
  • 12.2 Pfizer
  • 12.3 Johnson & Johnson
  • 12.4 Novartis
  • 12.5 Roche
  • 12.6 AbbVie
  • 12.7 Sanofi
  • 12.8 Amgen
  • 12.9 Celgene
  • 12.10 Gilead Sciences
  • 12.11 GlaxoSmithKline
  • 12.12 Bristol-Myers Squibb
  • 12.13 Biogen
  • 12.14 Eli Lilly
  • 12.15 Regeneron Pharmaceuticals
  • 12.16 Medtronic
  • 12.17 MedImmune

List of Tables

  • Table 1 Global Nanoparticles for Drug Delivery Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Nanoparticles for Drug Delivery Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Nanoparticles for Drug Delivery Market Outlook, By Liposomes (2024-2032) ($MN)
  • Table 4 Global Nanoparticles for Drug Delivery Market Outlook, By Niosomes (2024-2032) ($MN)
  • Table 5 Global Nanoparticles for Drug Delivery Market Outlook, By Micelles (2024-2032) ($MN)
  • Table 6 Global Nanoparticles for Drug Delivery Market Outlook, By Solid Lipid Nanoparticles (2024-2032) ($MN)
  • Table 7 Global Nanoparticles for Drug Delivery Market Outlook, By Nanoemulsions (2024-2032) ($MN)
  • Table 8 Global Nanoparticles for Drug Delivery Market Outlook, By Polymeric Nanoparticles (2024-2032) ($MN)
  • Table 9 Global Nanoparticles for Drug Delivery Market Outlook, By Material (2024-2032) ($MN)
  • Table 10 Global Nanoparticles for Drug Delivery Market Outlook, By Lipid-Based (2024-2032) ($MN)
  • Table 11 Global Nanoparticles for Drug Delivery Market Outlook, By Polymer-Based (2024-2032) ($MN)
  • Table 12 Global Nanoparticles for Drug Delivery Market Outlook, By Metallic (2024-2032) ($MN)
  • Table 13 Global Nanoparticles for Drug Delivery Market Outlook, By Quantum Dots (2024-2032) ($MN)
  • Table 14 Global Nanoparticles for Drug Delivery Market Outlook, By Dendrimers (2024-2032) ($MN)
  • Table 15 Global Nanoparticles for Drug Delivery Market Outlook, By Carbon-Based (2024-2032) ($MN)
  • Table 16 Global Nanoparticles for Drug Delivery Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 17 Global Nanoparticles for Drug Delivery Market Outlook, By Oral (2024-2032) ($MN)
  • Table 18 Global Nanoparticles for Drug Delivery Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 19 Global Nanoparticles for Drug Delivery Market Outlook, By Topical (2024-2032) ($MN)
  • Table 20 Global Nanoparticles for Drug Delivery Market Outlook, By Pulmonary (2024-2032) ($MN)
  • Table 21 Global Nanoparticles for Drug Delivery Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 22 Global Nanoparticles for Drug Delivery Market Outlook, By Ocular (2024-2032) ($MN)
  • Table 23 Global Nanoparticles for Drug Delivery Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 24 Global Nanoparticles for Drug Delivery Market Outlook, By Application (2024-2032) ($MN)
  • Table 25 Global Nanoparticles for Drug Delivery Market Outlook, By Cancer Therapy (2024-2032) ($MN)
  • Table 26 Global Nanoparticles for Drug Delivery Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 27 Global Nanoparticles for Drug Delivery Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 28 Global Nanoparticles for Drug Delivery Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 29 Global Nanoparticles for Drug Delivery Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 30 Global Nanoparticles for Drug Delivery Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Nanoparticles for Drug Delivery Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Nanoparticles for Drug Delivery Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Nanoparticles for Drug Delivery Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 34 Global Nanoparticles for Drug Delivery Market Outlook, By Biotechnology Firms (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.